Back to Archived News
Apollo Pharmaceutical, Inc. Announces Grant of a Joint US Patent for Encapsulated Mahonia Aquifolium (Psorberine)
Wednesday, June 06, 2007
Apollo Pharmaceutical, Inc. (www.apollorx.net) reported the grant of a US patent (# 7,205,006) for encapsulated Mahonia Aquifolium Extract, Extraction Process and Pharmaceutical composition containing the same. The patent has been jointly issued to IGI and Prime Pharmaceutical. Apollo Pharmaceutical holds the exclusive worldwide licensing rights for all potential commercial applications of Psorberine.
Apollo Pharmaceutical reported positive results from a 200 patient, 12 week, randomized, double blind, and a placebo controlled study to assess the efficacy and safety of Relieva™ topical cream in patients with mild to moderate Psoriasis. Psoriasis is a common skin disorder that affects approximately 9 million people in North America alone.
The Relieva™ cream, lotion and shampoo products were developed by scientists at IGI using the Novasome® technology to encapsulate and deliver Mahonia Aquifolium (Psorberine) to Psoriatic plaque.
Relieva cream and lotion are currently available for purchase at www.relieva.com and select pharmacies and physician's offices across Canada and the US. Relieva shampoo will be available by mid-summer, with Eczema (atopic dermatitis) products currently in the development stages.
"This further attests the capability of Novasome® encapsulation technology to enhance the delivery of active molecules to the skin…" said Rajiv Mathur, President and CEO of IGI, Inc.
Apollo Pharmaceutical Inc. (www.apollorx.net) is an exciting new healthcare company with a remarkable combination of talented people and advanced technologies, with a goal of bringing to market uniquely effective dermatology products.
Back to Archived News
